NCT02978326 - A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

November 15, 2018

Study Completion Date

December 11, 2018

Conditions

Postpartum Depression

Interventions

DRUG

SAGE-217 15/20 mg Oral Solution

SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).

DRUG

Placebo

SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.

DRUG

SAGE 217 30 mg Capsules

SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.

Trial Locations (27)

10036

Sage Investigational Site, New York

11030

Sage Investigational Site, Manhasset

20011

Sage Investigational Site, Washington D.C.

27599

Sage Investigational Site, Chapel Hill

27612

Sage Investigational Site, Raleigh

30030

Sage Investigational Site, Decatur

30331

Sage Investigational Site, Atlanta

32502

Sage Investigational Site, Pensacola

32807

Sage Investigational Site, Orlando

33027

Sage Investigational Site, Aventura

33173

Sage Investigational Site, Miami

33782

Sage Investigational SIte, Pinellas Park

42303

Sage Investigational Site, Owensboro

60169

Sage Investigational Site, Hoffman Estates

63304

Sage Investigational Site, Saint Charles

70115

Sage Investigational Site, New Orleans

70629

Sage Investigational Site, Lake Charles

72209

Sage Investigational Site, Little Rock

75080

Sage Investigational Site, Richardson

76060

Sage Investigational Site, Fort Worth

77058

Sage Investigational Site, Houston

84058

Sage Investigational Site, Orem

89102

Sage Investigational Site, Las Vegas

90212

Sage Investigational Site, Beverly Hills

92056

Sage Investigational Site, Oceanside

92595

Sage Investigational Site, Wildomar

02904

Sage Investigational Site, Providence